GNLX - חוב לטווח קצר להון Genelux Corp

The development of innovative tumor-fighting methods is being conducted within a stable US legal framework without sanction risks. The business model is based on the success of the Olvi-Vec system and the protection of immunotherapy patents, with the metric standing at 0.03. The asset's price trajectory is presented below. Genelux Corporation (GNLX) creates cutting-edge medicines by combining its scientific resources with specialized research centers to conduct joint clinical trials.

This ratio measures the dependence of equity on liabilities with a maturity exceeding one year. By analyzing the current trend of short-term liabilities to equity, an investor assesses the balance between financial leverage and liquidity risk. An increase in this metric signals a rising debt load, which could lead to a cash deficit. For Genelux Corporation (GNLX), this is critical when financing the costly cold chain transportation of viral vectors.